Phaseline

Targets › ITGA4

ITGA4 (Integrin alpha-4): drug programs, companies and trials

10 programs from 10 companies in 52 trials: 19 Phase 2, 17 Phase 3, 11 Phase 4, 5 Phase 1; Immunology, Oncology, Neurology; next expected readout Dec 2026.

Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. (UniProt, P13612)

Open in Phaseline: the race on ITGA4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaVedolizumab
Integrin alpha-4/beta-7 inhibitor
ITGA4, ITGB7Phase 4Ulcerative Colitis; Crohn's Disease; Crohn's Disease (CD); Moderately to Severely Active Ulcerative Colitis …May 2027
The Cleveland ClinicNatalizumab
Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor
ITGA4, ITGB7, ITGB1Phase 4Multiple Sclerosis, Relapsing-RemittingJul 2027
RocheAfimkibart
Anti-integrin α4β7 monoclonal antibody
ITGA4, ITGB7, IL22RA1Phase 3Moderately to Severely Active Ulcerative Colitis; Moderately to Severely Active Crohns Disease; Crohns Disease; Atopic Dermatitis …Dec 2026
ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.RAB001 (LLP2A-Alendronate)
LLP2A peptide targeting integrin alpha-4 beta-1 conjugated to alendronate
ITGA4Phase 2OsteonecrosisFeb 2027
Queen Mary University of LondonNatalizumab
Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor
ITGA4, ITGB7, ITGB1Phase 2Multiple SclerosisOct 2027
Gilead Sciencesemvistegrast (GS-1427)
α4 integrin antagonist
ITGA4Phase 2Ulcerative ColitisApr 2028
University of Michigan Rogel Cancer CenterNatalizumab
Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor
ITGA4, ITGB7, ITGB1Phase 2Recurrent Diffuse Large B-Cell LymphomaMay 2028
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)MORF-057
Selective integrin α4β7 inhibitor
ITGA4, ITGB7Phase 2Inflammatory Bowel DiseasesSep 2028
First Affiliated Hospital of Zhejiang UniversityA-CAR028
Bispecific chimeric antigen receptor T-cell targeting CD33 and CLL-1
CD33, ITGA4Phase 1Acute Myeloid Leukemia (AML)Dec 2026
7 Hills PharmaAlintegimod
α4β7 integrin antagonist
ITGA4, ITGB7Phase 1Advanced CancerDec 2027

Conditions

Ulcerative Colitis (12) Moderately to Severely Active Ulcerative Colitis (5) Crohn's Disease (4) Moderately to Severely Active Crohns Disease (3) Crohn Disease (2) Acute Lymphoblastic Leukemia (2) Atopic Dermatitis (2) Rheumatoid Arthritis (2) Inflammatory Bowel Diseases (2) Osteonecrosis (1) Crohn's Disease (CD) (1) Pouchitis (1)

Modalities

small molecule (3), antibody (3), mixed (3), protein or peptide (1)

Companies

ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. (1) Takeda (1) Roche (1) University of Michigan Rogel Cancer Center (1) Queen Mary University of London (1) Gilead Sciences (1) 7 Hills Pharma (1) The Cleveland Clinic (1) Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (1) First Affiliated Hospital of Zhejiang University (1)

Related targets

ITGB7 (7) ITGB1 (3) IL22RA1 (1) CD33 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.